Exhibit 10.6.2


 


THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE,
PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.


 


WARRANT
TO PURCHASE COMMON STOCK


 


	Company:	 	HUMACYTE,
INC., a Delaware corporation



	Number of
Shares of Common Stock:	 	 547,808 (the “Initial Shares”), plus all Additional Shares (as defined in Section 1.7) which
Holder is entitled to purchase



	Warrant Price:	 	 $2.699 per share, subject to adjustment



	Issue Date:	 	 March 30, 2021



	Expiration Date:	 	 March 30, 2031 See also Section 6.1(b).






	Credit
                            Facility:	 	This
Warrant to Purchase Common Stock (as the same may from time to time be amended, modified, supplemented or restated, “Warrant”)
is issued in connection with that certain Loan and Security Agreement of even date herewith among Silicon Valley Bank, SVB Innovation
Credit Fund VIII, L.P., the Company and any other Borrower that becomes party thereto (as the same may from time to time be amended,
modified, supplemented or restated, the “Loan Agreement”).



 


THIS
WARRANT CERTIFIES THAT, for good and valuable consideration, SVB Innovation Credit Fund VIII,
L.P. (together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof,
“Holder”) is entitled to purchase the number of fully paid and non-assessable shares (the “Shares”)
of the above-stated common stock (the “Common Stock”) of the above-named company (the “Company”)
at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the
provisions and upon the terms and conditions set forth in this Warrant. Capitalized terms used, but not otherwise defined herein shall
have the meanings set forth in the Loan Agreement.


 


SECTION
1. EXERCISE.


 


1.1
Method of Exercise. Holder may at any time and from time to time on any Business Day during the Term exercise this Warrant, in
whole or in part, by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially
the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2,
a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company
for the aggregate Warrant Price for the Shares being purchased.


 






     


     


    

 


1.2
Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified
in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares
equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue
to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula:


 


X
= Y(A-B)/A


 


where:


 


		X =	the
                                            number of Shares to be issued to the Holder;



 


		Y =	the
                                            number of Shares with respect to which this Warrant is being exercised (inclusive of the
                                            Shares surrendered to the Company in payment of the aggregate Warrant Price);



 


		A =	the
                                            fair market value (as determined pursuant to Section 1.3 below) of one Share; and



 


		B =	the
                                            Warrant Price.



 


1.3
Fair Market Value. If the Company’s Common Stock is then traded or quoted on a nationally recognized securities exchange,
inter-dealer quotation system or over-the-counter market (a “Trading Market”), the fair market value of a Share
shall be the closing price or last sale price of a share of Common Stock reported for the Business Day immediately before the date on
which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s Common Stock is not traded
in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith
judgment.


 


1.4
Delivery of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the manner set forth
in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon
such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Shares
not so acquired.


 


1.5
Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation
of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form,
substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the
Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount.


 






    2


     


    

 


1.6
Treatment of Warrant upon Acquisition of Company.


 


(a)
Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related
transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of
the Company; (ii) any merger or consolidation of the Company into or with another person or entity (other than a merger or consolidation
effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the
Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own less than a majority of the
Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation
or reorganization; or (iii) any sale or other transfer by the stockholders of the Company of shares representing at least a majority
of the Company’s then-total outstanding combined voting power. For the avoidance of doubt, and notwithstanding anything herein
to the contrary, the parties hereto acknowledge and agree that, for all purposes under this Warrant, the SPAC Transaction (as defined
in the Loan Agreement) does not constitute an Acquisition.


 


(b)
Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the Company’s
stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public
Acquisition”), and the fair market value of one Share as determined in accordance with Section 1.3 above would be
greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder has not exercised
this Warrant pursuant to Section 1.1 above as to all Shares, then this Warrant shall automatically be deemed to be exercised pursuant
to Section 1.2 above (a “Cashless Exercise”) as to all Shares effective immediately prior to and contingent
upon the consummation of a Cash/Public Acquisition. In connection with such Cashless Exercise, Holder shall be deemed to have restated
each of the representations and warranties in Section 4 of the Warrant as of the date thereof and the Company shall promptly notify
the Holder of the number of Shares (or such other securities) issued upon exercise. In the event of a Cash/Public Acquisition where the
fair market value of one Share as determined in accordance with Section 1.3 above would be less than the Warrant Price in effect
immediately prior to such Cash/Public Acquisition, then this Warrant will expire immediately prior to the consummation of such Cash/Public
Acquisition.


 


(c)
Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor entity
shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property
as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding
on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this
Warrant.


 


(d)
As used in this Warrant, “Marketable Securities” means securities meeting all of the following
requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of
all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other
security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on
or prior to the closing thereof is then traded in a Trading Market, and (iii) following the closing of such Acquisition, Holder
would not be restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received by
Holder in such Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of such Acquisition,
except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations,
and (y) does not extend beyond six (6) months from the closing of such Acquisition.


 






    3


     


    

 


(e)
Notwithstanding anything herein to the contrary, upon the closing of the SPAC Transaction, this Warrant shall be canceled in exchange
for a Rollover Warrant as defined in and in accordance with the Business Combination Agreement (as defined in the Loan Agreement).


 


1.7
Number of Shares. The number of Shares for which this Warrant is exercisable shall be equal to (a) the Initial Shares, plus
(b) upon Lenders making the Term B Loan Advance to the Company, an additional number of Shares equal to 234,775 (the “Additional
Shares”). For clarity, the total number of Shares for which this Warrant shall be exercisable shall not exceed 782,583
(subject to adjustment in accordance with Section 2 below).


 


SECTION
2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.


 


2.1
Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Common
Stock payable in securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall
receive, without additional cost to Holder, the total number and kind of securities and property which Holder would have received had
Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares
of the Common Stock by reclassification or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall
be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Common Stock
are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately
increased and the number of Shares shall be proportionately decreased.


 


2.2
Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Common Stock
are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or
series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and series of Company
securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to
further adjustment thereafter from time to time in accordance with the provisions of this Warrant. The provisions of this Section 2.2
shall similarly apply to successive reclassifications, exchanges, combinations, substitutions, replacements or other similar events.


 


2.3
Intentionally Omitted.


 


2.4
Intentionally Omitted.


 


2.5
No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company
shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional interest by
(i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective
Warrant Price.


 






    4


     


    

 


2.6
Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, class and/or number of Shares pursuant to Section
2.1 or 2.2, the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments
to the Warrant Price, class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written request
from Holder, furnish Holder with a certificate of its Chief Financial Officer setting forth computations of such adjustment and the Warrant
Price, class and number of Shares in effect upon the date of such adjustment.


 


SECTION
3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.


 


3.1
Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:


 


(a)
The number of Initial Shares first set forth above, together with the Additional Shares first set forth above, collectively represent
not less than 0.25% of the Company’s total issued and outstanding shares of Common Stock, calculated on and as of the Issue Date
hereof on a fully-diluted basis assuming the conversion into Common Stock of all outstanding securities and instruments (including, without
limitation, outstanding securities deemed to be convertible by their terms into shares of Common Stock (regardless of whether such securities
or instruments are by their terms now so convertible)); provided, however, that it is hereby understood and agreed that shares of Common
Stock reserved for issuance under the Company’s incentive stock and stock option plans and not then subject to outstanding grants
or options are not included in such calculation.


 


(b)
The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of the
Company’s Common Stock or options to purchase shares of the Company’s Common Stock were valued in the Company’s most
recent 409(a) valuation.


 


(c)
All Shares which may be issued upon the exercise of this Warrant pursuant to the terms hereof, shall, upon issuance, be duly authorized,
validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for (i) restrictions on transfer provided
for herein and under applicable federal and state securities laws, (ii) restrictions on transfer and other liens and encumbrances set
forth in the Company’s Operating Documents, the Amended and Restated Right of First Refusal and Co-Sale Agreement of the Company,
dated as of June 25, 2018, as amended, modified, supplemented or restated from time to time (the “ROFR Co-Sale Agreement”),
the Amended and Restated Investors’ Rights Agreement of the Company, dated as of June 25, 2018, as amended, modified, supplemented
or restated from time to time (the “IRA”), and the Amended and Restated Voting Agreement of the Company, dated
as of June 25, 2018, as amended, modified, supplemented or restated from time to time (the “Voting Agreement”),
and (iii) liens and encumbrances created by or imposed by the Holder. The Company covenants that it shall at all times cause to be reserved
and kept available out of its authorized and unissued capital stock such number of securities as will be sufficient to permit the exercise
in full of this Warrant.


 


(d)
The Company’s capitalization table attached hereto as Schedule 1 is true and complete, in all material respects, as of the
Issue Date.


 






    5


     


    

 


3.2
Notice of Certain Events. If the Company proposes at any time to:


 


(a)
declare any dividend or distribution upon the outstanding shares of the Company’s Common Stock, whether in cash, property, stock,
or other securities and whether or not a regular cash dividend;


 


(b)
offer for subscription or sale pro rata to the holders of the outstanding shares of the Company’s Common Stock any additional shares
of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights);


 


(c)
effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the
Company’s Common Stock;


 


(d)
effect an Acquisition or to liquidate, dissolve or wind up; or


 


(e)
effect its initial, underwritten offering and sale of its securities to the public pursuant to an effective registration statement under
the Act (the “IPO”);


 


then,
in connection with each such event, the Company shall give Holder:


 


(1)
in the case of the matters referred to in (a) and (b) above, at least seven (7) Business Days prior written notice of
the earlier to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription
rights (and specifying the date on which the holders of outstanding shares of the Common Stock will be entitled thereto) or for determining
rights to vote, if any;


 


(2)
in the case of the matters referred to in (c) and (d) above at least seven (7) Business Days prior written notice of the
date when the same will take place (and specifying the date on which the holders of outstanding shares of Common Stock will be entitled
to exchange their shares for the securities or other property deliverable upon the occurrence of such event and such reasonable information
as Holder may reasonably require regarding the treatment of this Warrant in connection with such event giving rise to the notice); and


 


(3)
with respect to the IPO, at least seven (7) Business Days prior written notice of the date on which the Company proposes to publicly
file its registration statement in connection therewith.


 


Company
will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting
or reporting requirements.


 


For
the avoidance of doubt, the Company shall not be required to deliver any notice to the Holder under this Section 3.2 in connection with
the SPAC Transaction.


 






    6


     


    

 


SECTION
4. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE
HOLDER.


 


The
Holder represents, warrants and covenants to the Company as follows:


 


4.1
Purchase for Own Account. This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder are being acquired
for investment for Holder’s own account, not as a nominee or agent, and not with a view towards, or for resale in connection with,
the public sale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose
of acquiring this Warrant or the Shares.


 


4.2
Disclosure of Information. Holder is aware of the Company’s business affairs and financial condition and has received or
has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect
to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive
answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain
additional information necessary to verify any information furnished to Holder or to which Holder has access.


 


4.3
Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear
the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience
in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its
underlying securities and has a preexisting personal or business relationship with the Company and certain of its officers, directors
or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances
of such persons. Holder is able, without materially impairing its financial condition, to hold the Shares to be issued upon exercise
of this Warrant for an indefinite period of time.


 


4.4
Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under
the Act.


 


4.5
The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the
Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s
investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof are “restricted
securities” under the federal securities laws and must be held indefinitely unless subsequently registered under the Act and qualified
under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder
is aware of the provisions of Rule 144 promulgated under the Act, and understands the resale limitations imposed thereby and by the Act.


 






    7


     


    

 


4.6
Market Stand-off Agreement. Holder agrees that this Warrant and the Shares shall be subject to the market stand-off provisions
in Section 2.10 of the IRA; provided, however, that from and after the closing of the SPAC Transaction, this Warrant and the Shares
shall be subject to the market stand-off provisions set forth in the Investor Rights and Lock-Up Agreement that will be executed by the
Company, Alpha Healthcare Acquisition Corp. and certain of their respective stockholders at the closing of the SPAC Transaction so long
as all stockholders who own, as of immediately prior to the closing of the SPAC Transaction, at least five percent (5.00%) of the fully
diluted ownership of the Company as of such time are also party to such agreement.


 


4.7
No Voting or Other Rights. Holder, as a Holder of this Warrant, will not have any voting rights, or any other rights as a stockholder
of the Company, until the exercise of this Warrant.


 


4.8
Stockholder Agreements. Upon any exercise of this Warrant into Shares prior to the closing of the SPAC Transaction and as a condition
to the issuance of the Shares, Holder shall, if requested by the Company, become party to each of the Voting Agreement and the ROFR Co-Sale
Agreement (and the Shares issued to the Holder upon such exercise shall be subject to the respective terms thereof) so long as all stockholders
who own, as of immediately prior to the closing of the SPAC Transaction, at least five percent (5.00%) of the fully diluted ownership
of the Company as of such time are also party to such agreements.


 


SECTION
5. GOVERNING LAW, VENUE, JURY TRIAL WAIVER.


 


5.1
Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of New York, without giving
effect to its principles regarding conflicts of law.


 


5.2
Jurisdiction and Venue. The Company and Holder each submit to the exclusive jurisdiction of the State and Federal courts in New
York, New York, Borough of Manhattan; provided, however, that nothing in this Warrant shall be deemed to operate to preclude Holder from
bringing suit or taking other legal action in any other jurisdiction to enforce a judgment or other court order in favor of Holder. The
Company expressly submits and consents in advance to such jurisdiction in any action or suit commenced in any such court, and the Company
hereby waives any objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby
consents to the granting of such legal or equitable relief as is deemed appropriate by such court. The Company hereby waives personal
service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons, complaints,
and other process may be made by registered or certified mail addressed to the Company at the address set forth in, or subsequently provided
by the Company in accordance with, Section 6.5 of this Warrant and that service so made shall be deemed completed upon the earlier to
occur of the Company’s actual receipt thereof or three (3) days after deposit in the U.S. mails, proper postage prepaid.


 


5.3
Jury Trial Waiver. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE COMPANY AND HOLDER EACH WAIVE THEIR RIGHT TO A JURY
TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS WARRANT, THE LOAN AGREEMENT OR ANY CONTEMPLATED TRANSACTION,
INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR THE PARTIES’ AGREEMENT
TO THIS WARRANT. EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.


 


5.4
Survival. This Section 5 shall survive the termination of this Warrant.


 






    8


     


    

 


SECTION
6. MISCELLANEOUS.


 


6.1
Term and Automatic Conversion upon Expiration.


 


(a)
Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from
time to time on or before 6:00 PM, Eastern time, on the Expiration Date and shall be void thereafter (the “Term”).


 


(b)
Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or
other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant
Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2
above as to all Shares (or such other securities) for which it shall not previously have been exercised, and subject to Section 4.8,
the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such
exercise to Holder.


 


6.2
Legends. The Shares shall be imprinted with a legend in substantially the following form:


 


THE
SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE COMMON STOCK ISSUED BY THE ISSUER TO
SVB Innovation Credit Fund VIII, L.P. DATED MARCH 30, 2021, MAY NOT BE OFFERED, SOLD,
PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER,
SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.


 


6.3
Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities
issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except
in compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation,
the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested
by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to any affiliate of Holder,
provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act. Additionally,
the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated
under the Act.


 






    9


     


    

 


6.4
Transfer Procedure. Subject to the provisions of Sections 4.8 and 6.3 and upon providing the Company with written notice,
Holder and any subsequent Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant to any
permitted transferee, provided, however, in connection with any such transfer, Holder or any subsequent Holder will give the Company
notice of the portion of the Warrant or the Shares being transferred with the name, address and taxpayer identification number of the
permitted transferee and Holder will surrender this Warrant to the Company for reissuance to the permitted transferee(s) (and Holder
if applicable); and provided further, that any subsequent permitted transferee shall agree in writing with the Company to be bound by
all of the terms and conditions of this Warrant. Notwithstanding any contrary provision herein, prior to the closing of an IPO or the
SPAC Transaction, Holder may not, without the Company’s prior written consent, transfer this Warrant or any portion hereof, or
any Shares issued upon any exercise hereof, to any person or entity who directly competes with the Company, except in connection with
an Acquisition of the Company by such a direct competitor.


 


6.5
Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered
and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered
or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed
in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier
fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company
or such Holder from time to time in accordance with the provisions of this Section 6.5. All notices to Holder shall be addressed
as follows until the Company receives notice of a change of address in connection with a transfer or otherwise:


 


SVB
Innovation Credit Fund VIII, L.P.


c/o
SVB Capital


2770
Sand Hill Road


Menlo
Park, CA 94025


Attn:
SVB Capital Finance and Operations


 


All
notices to the Company shall be addressed as follows until Holder receives notice of a change in address:


 


Humacyte,
Inc.


2525
E. NC Highway 54


Durham,
NC 27713


Attn:
Chief Financial Officer


 






    10


     


    

 


with
a copy to:


 


Humacyte,
Inc.


2525
E. NC Highway 54


Durham,
NC 27713


Attn:
Director of Strategic Finance


 


6.6
Waiver. Notwithstanding any contrary provision herein or in the Loan Agreement but subject to Section 1.6(e) hereof, this Warrant
and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular instance and either retroactively
or prospectively) only by an instrument in writing signed by Holder and the Company.


 


6.7
Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable
attorneys’ fees.


 


6.8
Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall constitute
one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original
signature page with regards to any agreement subject to the terms hereof or any amendment thereto.


 


6.9
Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning
of any provision of this Warrant.


 


6.10 Business
Days. “Business Day” is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank
is closed.


 


 


[Remainder
of page left blank intentionally]


 


[Signature page follows]


 






    11


     


    

 


IN
WITNESS WHEREOF, the parties have caused this Warrant to Purchase Common Stock to be executed by their duly authorized representatives
effective as of the Issue Date written above.


 


“COMPANY”


 


HUMACYTE, INC.


 


	By:	/s/ Douglas Blankenship 	 
	Name:	Douglas Blankenship 	 
	Title:	Chief Financial Officer 	 



 


“HOLDER”


 


SVB Innovation Credit Fund
VIII, L.P.


By: SVB Innovation Credit Partners VIII, LLC, a


Delaware limited liability company, its General


Partner


 


	By:	/s/ Ryan Grammer 	 
	Name:	Ryan Grammer 	 
	Title:	Senior Managing Director 	 


 


 


[Signature
Page to Warrant to Purchase Common Stock]


 






     


     


    

 


APPENDIX
1



NOTICE OF EXERCISE OF WARRANT


 


1.
The undersigned Holder hereby exercises its right to purchase ___________ shares of the Common Stock of HUMACYTE, INC. (the
“Company”) in accordance with the attached Warrant to Purchase Common Stock, and tenders payment of the
aggregate Warrant Price for such shares as follows:


 


		[
                              ]	check
in the amount of $________ payable to the order of the Company enclosed herewith



 


		[
                              ]	Wire
transfer of immediately available funds to the Company’s account



 


		[  
                            ]	Cashless
Exercise pursuant to Section 1.2 of the Warrant



 


		[  
                            ]	Other
[Describe] __________________________________________



 


2.
Please issue a certificate or certificates representing the Shares in the name specified below:


 


	 	 	 
	 	Holder’s
Name	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	(Address)	 


 


3.
By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in
Section 4 of the Warrant to Purchase Common Stock as of the date hereof.


 


	 	HOLDER:
	 	 
	 	 	 
	 	By:	 
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 
	 	 	 
	 	(Date):